The Illumina-backed cellular technology developer has closed $12m in a series A round led by HBM Genomics.
Xcell Biosciences, a US-based cell culturing platform developer backed by gene editing company Illumina, completed a $12m series A round led by HBM Genomics yesterday.
HBM Genomics, a subsidiary of investment firm HBM Healthcare Investments, was joined in the round by all Xcell’s “major existing investors”.
Xcell’s lead product is a cell culturing platform called the Avatar system which replicates the conditions found in vivo environments to help drug developers and researchers produce relevant, reproducible results while working on cellular…
